Author details

Full Name

Erich Jaeger

Affiliation

Illumina Inc.

ORCID

Career Start Year

2001

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
35953477	Ultra-deep sequencing validates safety of CRISPR/Cas9 genome editing in human hematopoietic stem and progenitor cells.	Nat Commun	2022
35953477	Ultra-deep sequencing validates safety of CRISPR/Cas9 genome editing in human hematopoietic stem and progenitor cells.	Nat Commun	2022
36514120	Structural variant analysis of a cancer reference cell line sample using multiple sequencing technologies.	Genome Biol	2022
36514120	Structural variant analysis of a cancer reference cell line sample using multiple sequencing technologies.	Genome Biol	2022
34504346	Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing.	Nat Biotechnol	2021
34504347	Establishing community reference samples, data and call sets for benchmarking cancer mutation detection using whole-genome sequencing.	Nat Biotechnol	2021
34504346	Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing.	Nat Biotechnol	2021
34504347	Establishing community reference samples, data and call sets for benchmarking cancer mutation detection using whole-genome sequencing.	Nat Biotechnol	2021
30698692	New de novo assembly of the Atlantic bottlenose dolphin (Tursiops truncatus) improves genome completeness and provides haplotype phasing.	Gigascience	2019
30698692	New de novo assembly of the Atlantic bottlenose dolphin (Tursiops truncatus) improves genome completeness and provides haplotype phasing.	Gigascience	2019
28650462	Haplotype phasing of whole human genomes using bead-based barcode partitioning in a single tube.	Nat Biotechnol	2017
28650462	Haplotype phasing of whole human genomes using bead-based barcode partitioning in a single tube.	Nat Biotechnol	2017
27271295	Extensive sequencing of seven human genomes to characterize benchmark reference materials.	Sci Data	2016
27271295	Extensive sequencing of seven human genomes to characterize benchmark reference materials.	Sci Data	2016
25634010	Diagnostic Mutation Profiling and Validation of Non-Small-Cell Lung Cancer Small Biopsy Samples using a High Throughput Platform.	J Thorac Oncol	2015
25634010	Diagnostic Mutation Profiling and Validation of Non-Small-Cell Lung Cancer Small Biopsy Samples using a High Throughput Platform.	J Thorac Oncol	2015
25985263	Comprehensive transcriptome analysis using synthetic long-read sequencing reveals molecular co-association of distant splicing events.	Nat Biotechnol	2015
25985263	Comprehensive transcriptome analysis using synthetic long-read sequencing reveals molecular co-association of distant splicing events.	Nat Biotechnol	2015
23552698	Genomic copy number alterations in clear cell renal carcinoma: associations with case characteristics and mechanisms of VHL gene inactivation.	Oncogenesis	2012
23552698	Genomic copy number alterations in clear cell renal carcinoma: associations with case characteristics and mechanisms of VHL gene inactivation.	Oncogenesis	2012
21641572	A methyl-deviator epigenotype of estrogen receptor-positive breast carcinoma is associated with malignant biology.	Am J Pathol	2011
22022277	Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.	PLoS Genet	2011
21641572	A methyl-deviator epigenotype of estrogen receptor-positive breast carcinoma is associated with malignant biology.	Am J Pathol	2011
22022277	Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.	PLoS Genet	2011
20069569	Identification and functional relevance of de novo DNA methylation in cancerous B-cell populations.	J Cell Biochem	2010
20137853	TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe.	Cancer Lett	2010
20069569	Identification and functional relevance of de novo DNA methylation in cancerous B-cell populations.	J Cell Biochem	2010
20137853	TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe.	Cancer Lett	2010
19155300	Large-scale profiling of archival lymph nodes reveals pervasive remodeling of the follicular lymphoma methylome.	Cancer Res	2009
19155300	Large-scale profiling of archival lymph nodes reveals pervasive remodeling of the follicular lymphoma methylome.	Cancer Res	2009
18635227	von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.	J Urol	2008
18676741	Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.	Clin Cancer Res	2008
18635227	von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.	J Urol	2008
18676741	Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.	Clin Cancer Res	2008
16827904	Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.	BJU Int	2006
16827904	Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.	BJU Int	2006
14618610	Inhibition of prostate cancer metastatic colonization by approximately 4.2 Mb of human chromosome 12.	Int J Cancer	2004
14618610	Inhibition of prostate cancer metastatic colonization by approximately 4.2 Mb of human chromosome 12.	Int J Cancer	2004
12618387	Molecular evolution of the Escherichia coli chromosome. VI. Two regions of high effective recombination.	Genetics	2003
12618387	Molecular evolution of the Escherichia coli chromosome. VI. Two regions of high effective recombination.	Genetics	2003
12085966	Metastasis suppression in prostate cancer.	Cancer Metastasis Rev	2001
12085966	Metastasis suppression in prostate cancer.	Cancer Metastasis Rev	2001

1 - 42 of 42

Matti Annala

University of British Columbia

Career Start Year 2011

Number of shared co-authors 2

David A Quigley

University of California-San Francisco

Career Start Year 2008

Number of shared co-authors 2

Jamie K Teer

H. Lee Moffitt Cancer Center and Research Institute

Career Start Year 2005

Number of shared co-authors 2

Jianmin Wang

Roswell Park Comprehensive Cancer Center

Career Start Year 2003

Number of shared co-authors 1

Trevor J Pugh

Princess Margaret Cancer Centre, University Health Network

Career Start Year 2003

Number of shared co-authors 1

Sooryanarayana Varambally

University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center

Career Start Year 2001

Number of shared co-authors 0

Andrea Sboner

Institute for Computational Biomedicine

Career Start Year 2000

Number of shared co-authors 2

Srinivasan Yegnasubramanian

Johns Hopkins University School of Medicine

Career Start Year 1999

Number of shared co-authors 0

Colin C Pritchard

University of Washington, USA Brotman Baty Institute for Precision Medicine

Career Start Year 1999

Number of shared co-authors 3

Xuhong Cao

Michigan Center for Translational Pathology.

Career Start Year 1999

Number of shared co-authors 0

Michal R Schweiger

Institute for Translational Epigenetics, University of Cologne

Career Start Year 1999

Number of shared co-authors 0

Tobias Sj??blom

Uppsala University

Career Start Year 1999

Number of shared co-authors 1

Anna Lapuk

Contextual Genomics Inc.

Career Start Year 1998

Number of shared co-authors 0

Liang Wang

H. Lee Moffitt Cancer Center

Career Start Year 1996

Number of shared co-authors 2

Yi-Mi Wu

University of Michigan Medical School ann arbor

Career Start Year 1995

Number of shared co-authors 0

Anamaria A Camargo

Hospital Sirio-Libanes

Career Start Year 1994

Number of shared co-authors 0

Arul M Chinnaiyan

University of Michigan Medical School.

Career Start Year 1993

Number of shared co-authors 3

Adam B Olshen

12224University of California san francisco

Career Start Year 1993

Number of shared co-authors 1

Yong-Jie Lu

Barts Cancer Institute, Queen Mary University of London

Career Start Year 1993

Number of shared co-authors 1

Holger S??ltmann

German Cancer Research Center (DKFZ)

Career Start Year 1993

Number of shared co-authors 0

Phillip A Futreal

The University of Texas MD Anderson Cancer Center

Career Start Year 1991

Number of shared co-authors 1

Stanislav V Volik

University of British Columbia

Career Start Year 1991

Number of shared co-authors 2

Nisha Kanwar

University of Toronto, the Hospital for Sick Children.

Career Start Year 1989

Number of shared co-authors 0

Colin C Collins

University of British Columbia

Career Start Year 1988

Number of shared co-authors 4

Jonathan R Pollack

Stanford University School of Medicine

Career Start Year 1987

Number of shared co-authors 2

Eivind Hovig

Center for Bioinformatics, University of Oslo

Career Start Year 1987

Number of shared co-authors 2

Olli Kallioniemi

Karolinska Institute

Career Start Year 1984

Number of shared co-authors 6

Matthew Meyerson

Broad Institute

Career Start Year 1983

Number of shared co-authors 5

George Steven Bova

Prostate Cancer Research Center, Tampere University and Tays Cancer Center

Career Start Year 1982

Number of shared co-authors 7

Francesca Demichelis

University of Trento

Career Start Year 1969

Number of shared co-authors 7

row(s) 1 - 30 of 30

Chunlin Xiao

Chongqing Aier Eye Hospital

Co-authored papers 4

Christopher E Mason

Feil Family Brain and Mind Research Institute.

Co-authored papers 4

Paolo Boffetta

Co-authored papers 4

Ali Moshrefi

Illumina Inc.

Co-authored papers 4

Jian-Bing Fan

Nanfang Hospital and Basic Medical College, Southern Medical University

Co-authored papers 3

Maria J Merino

National Cancer Institute, National Institutes of Health

Co-authored papers 3

Wenming Xiao

Human Phenome Institute and Shanghai Cancer Center, Fudan University

Co-authored papers 3

Rebecca Kusko

Immuneering Corporation

Co-authored papers 3

Marina Bibikova

Departments of Bioinformatics and Clinical Genomics, Illumina Inc.

Co-authored papers 3

Stephen T Sherry

National Center for Biotechnology Information, National Institutes of Health

Co-authored papers 3

William Marston Linehan

Co-authored papers 3

Weida Tong

National Center for Toxicological Research

Co-authored papers 2

Baitang Ning

Co-authored papers 2

Susan R Davis

Co-authored papers 2

Sean Davis

Johns Hopkins School of Medicine, National Cancer Institute, Princeton University, University of Colorado Anschutz Medical Campus, University of Pittsburgh, University of Washington

Co-authored papers 2

Jonathan K Killian

From Foundation Medicine

Co-authored papers 2

Charles Lu

Co-authored papers 2

Huixiao Hong

Co-authored papers 2

Gary P Schroth

Co-authored papers 2

Ulrika Liljedahl

Co-authored papers 2